LncRNA SNHG7 promotes cardiac remodeling by upregulating ROCK1 via sponging miR-34-5p.


Journal

Aging
ISSN: 1945-4589
Titre abrégé: Aging (Albany NY)
Pays: United States
ID NLM: 101508617

Informations de publication

Date de publication:
06 06 2020
Historique:
received: 15 02 2020
accepted: 20 04 2020
pubmed: 9 6 2020
medline: 9 3 2021
entrez: 9 6 2020
Statut: ppublish

Résumé

Previous studies have shown that lncRNA small nuclear RNA host gene 7 (lncRNA SNHG7) played an important role in cancer progression. However, the role of lncRNA SNHG7 in cardiac fibrosis is still poorly understood. In this study, the results of quantitative real time polymerase chain reaction (qRT-PCR) analysis showed that lncRNA SNHG7 was over expressed in the infarcted and peri-infarcted area in the left ventricle after MI in mice. Western blot analysis showed that knockdown of SNHG7 decreased the expression of collagen type 1 (Col1)and α-smooth muscle actin (α-SMA). Echocardiographic study suggested that inhibition of SNHG7 improved cardiac function after MI in mice. Luciferase assay indicated SNHG7 could act as a competing endogenous RNA (ceRNA) by sponging miR-34-5p. The MTT cell proliferation assay and 5-ethynyl-2'-deoxyuridine (EdU) labelling assay revealed that co-transfection of SNHG7 and miR-34-5p inhibited cell viability and proliferation of cardiac fibroblasts (CF). All the results indicated that lncRNA SNHG7 could promote cardiac fibrosis via targeting miR-34-5p through acting as a ceRNA in mice after MI. Silencing of SNHG7 could attenuate deposition of collagens and improve cardiac function. miR-34-5p could suppress the fibrogenesis of CF by targeting ROCK1 and abolish SNHG7-induced CF proliferation and fibroblast-to-myofibroblast transition.

Identifiants

pubmed: 32507765
pii: 103269
doi: 10.18632/aging.103269
pmc: PMC7346013
doi:

Substances chimiques

MIRN34a microRNA, mouse 0
MicroRNAs 0
RNA, Long Noncoding 0
Rock1 protein, mouse EC 2.7.11.1
rho-Associated Kinases EC 2.7.11.1

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10441-10456

Références

J Mol Cell Cardiol. 2008 Mar;44(3):551-60
pubmed: 18178218
FASEB J. 2019 Oct 1;33(10):11180-11193
pubmed: 31295018
FASEB J. 2019 Jun;33(6):7348-7362
pubmed: 30848941
Sci Rep. 2017 Mar 07;7:43242
pubmed: 28266583
Theranostics. 2016 Sep 10;6(12):2068-2083
pubmed: 27698941
Circulation. 2016 Jan 19;133(3):291-301
pubmed: 26585673
FASEB J. 2020 Feb;34(2):2703-2714
pubmed: 31916627
Toxicol Lett. 2018 Oct 1;295:325-334
pubmed: 30010033
Hum Reprod Update. 2016 Dec;23(1):19-40
pubmed: 27655590
Mol Cancer. 2018 May 24;17(1):92
pubmed: 29793547
J Clin Invest. 2017 Dec 1;127(12):4498-4515
pubmed: 29130936
Cancer Cell. 2016 Apr 11;29(4):452-463
pubmed: 27070700
Eur Rev Med Pharmacol Sci. 2018 Jan;22(1):166-173
pubmed: 29364484
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Gastroenterology. 2019 Feb;156(3):676-691.e11
pubmed: 30445010
Mol Cancer. 2018 Mar 10;17(1):72
pubmed: 29523145
Nat Commun. 2013;4:2189
pubmed: 23877263
Annu Rev Immunol. 2017 Apr 26;35:177-198
pubmed: 28125358
Circ J. 2016 Jun 24;80(7):1491-8
pubmed: 27251065
Cell Mol Life Sci. 2014 Feb;71(4):549-74
pubmed: 23649149
Proc Natl Acad Sci U S A. 2018 Jul 24;115(30):E7129-E7138
pubmed: 29987023
J Cell Mol Med. 2018 Dec;22(12):5768-5775
pubmed: 30188595
Cell Death Dis. 2018 Jun 18;9(7):722
pubmed: 29915311
Virus Res. 2018 Sep 15;257:25-32
pubmed: 30165080
Eur J Pharmacol. 2019 Aug 5;856:172407
pubmed: 31132353
FASEB J. 2006 May;20(7):916-25
pubmed: 16675849
Cell Biosci. 2018 Dec 6;8:63
pubmed: 30534359
J Am Soc Nephrol. 2006 Nov;17(11):3105-14
pubmed: 17005937
Circulation. 2016 Nov 8;134(19):1484-1499
pubmed: 27821419
Int J Oncol. 2019 Oct;55(4):833-844
pubmed: 31485605
Methods Mol Biol. 2016;1402:271-286
pubmed: 26721498
Mol Cancer Res. 2018 Jan;16(1):124-134
pubmed: 28928287
Redox Biol. 2018 Sep;18:84-92
pubmed: 29986212
Cell. 2018 Jan 25;172(3):393-407
pubmed: 29373828
Cell Physiol Biochem. 2018;49(2):447-462
pubmed: 30153668
Eur Rev Med Pharmacol Sci. 2017 Oct;21(20):4613-4622
pubmed: 29131253
FASEB J. 2018 Oct;32(10):5285-5297
pubmed: 29683732
Theranostics. 2018 Feb 2;8(4):1180-1194
pubmed: 29464008
Blood. 2010 Mar 4;115(9):1785-96
pubmed: 20008297
FASEB J. 2019 Apr;33(4):5112-5125
pubmed: 30652956

Auteurs

Jie Wang (J)

Department of Cardiac Intervention, Linyi People's Hospital, Linyi 276000, Shandong, China.

Shouwen Zhang (S)

Department of Critical Care Medicine, Aerospace Center Hospital, Haidian, 100049, Beijing, China.

Xinhua Li (X)

Department of Critical Care Medicine, Aerospace Center Hospital, Haidian, 100049, Beijing, China.

Maolei Gong (M)

Department of Critical Medicine, Aerospace Center Hospital, Peking University School of Clinical Medicine, Beijing 100049, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH